Conditions: Tumors Characterized by Genetic Abnormalities of ALK
Keywords: ALK inhibitor, NSCLC, LDK378, ceritinib, genetic abnormalities
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 304
Healthy volunteers: no

Brief summary:
This study assessed the safety and efficacy of LDK378 in adult patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).

Detailed description:

Arms:
arm 1: NSCLC patients previously treated with an ALK inhibitor arm 2: NSCLC patients not previously treated with an ALK inhibitor arm 3: Patients with other tumors that are ALK positive other than NSCLC

Interventions: intervention 1: LDK378
Intervention descriptions: intervention 1: LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.

Protocol document: